Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
Status:
Terminated
Trial end date:
2019-06-08
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if Ofev® (nintedanib, also called
BIBF1120) can help to control IBC. The safety of this drug will also be studied.
This is an investigational study. Nintedanib is commercially available and FDA approved for
the treatment of certain types of lung disease. Its use in this study is investigational. The
study doctor can explain how the study drug is designed to work.
Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.